MDA

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022

by

Article content NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) —  BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment … Read more

D-BOX Technologies to Refile its MD&A for Fiscal Year Ended March 31, 2022 and its Financial Statements and MD&A for First Quarter of Fiscal 2023

by

This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Breadcrumb Trail Links GlobeNewswire Author of the article: Article content LONGUEUIL, Quebec, Aug. 18, 2022 (GLOBE NEWSWIRE) — D-BOX Technologies … Read more